Clinical Trials | February 28, 2026
Merck’s KEYTRUDA shows significant survival boost in platinum-resistant ovarian cancer
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
The TacroType test provides actionable genetic insights to help clinicians understand how individual patients metabolize tacrolimus
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Subscribe To Our Newsletter & Stay Updated
